Gastrointestinal Carcinoid Tumor Clinical Trial
Official title:
Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors
NCT number | NCT00227773 |
Other study ID # | CDR0000446076 |
Secondary ID | ECOG-E6203 |
Status | Withdrawn |
Phase | Phase 2 |
First received | September 26, 2005 |
Last updated | October 6, 2015 |
Verified date | October 2015 |
Source | Eastern Cooperative Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control
symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide
may be an effective treatment for neuroendocrine tumors.
PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide
works in treating patients with progressive neuroendocrine tumors.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed low-grade neuroendocrine tumors - The following tumor types are excluded: - Small cell lung cancer - Medullary thyroid cancer - Paraganglioma - Pheochromocytoma - Measurable disease - Radiographic evidence of disease progression after completion of any prior systemic therapy, chemoembolization, bland embolization, or observation within the past year, defined as either of the following: - Appearance of a new lesion - At least 20% increase in the longest diameter (LD) of any previously documented lesion or an increase in the sum of the LDs of multiple lesions in the aggregate of 20% PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count = 1,000/mm^3 - Platelet count = 75,000/mm^3 - Hemoglobin = 8.0 g/dL Hepatic - Bilirubin = 2.0 times upper limit of normal (ULN) - AST = 3 times ULN (5 times ULN if liver metastases are present) Renal - Creatinine = 1.5 times ULN - Meets 1 of the following criteria: - Urine protein negative by dipstick - Urine protein:creatinine ratio < 1.0 - Urine protein < 1 g by 24-hour urine collection Gastrointestinal - Must be able to swallow tablets - No ulcerative disease - No uncontrolled nausea, vomiting, or diarrhea - No bowel obstruction - No other gastrointestinal tract disease resulting in an inability to take oral medication Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Must be able to receive a contrast-enhanced CT scan - No known history of allergic reaction to vatalanib or its derivatives or octreotide injections PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - At least 4 weeks since prior chemotherapy - No more than 1 prior systemic chemotherapy regimen - Chemoembolization is not considered systemic chemotherapy - No concurrent chemotherapy Endocrine therapy - Not specified Radiotherapy - At least 3 weeks since prior radiotherapy - No concurrent radiotherapy Surgery - At least 4 weeks since prior major surgery Other - At least 4 weeks since other prior systemic therapy - At least 4 weeks since prior local liver therapy - No prior anti-vascular endothelial growth factor agents - No concurrent grapefruit or grapefruit juice - No concurrent therapeutic warfarin or similar oral anticoagulants that are metabolized by the cytochrome P450 system - Concurrent heparin allowed |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Eastern Cooperative Oncology Group | National Cancer Institute (NCI) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
Completed |
NCT00002470 -
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00454376 -
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
|
Phase 4 | |
Terminated |
NCT00002947 -
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00427349 -
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00416767 -
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00005049 -
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
|
Phase 2 | |
Completed |
NCT00027638 -
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00019474 -
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
|
Phase 2 | |
Terminated |
NCT00227617 -
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2/Phase 3 | |
Completed |
NCT00654160 -
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
Completed |
NCT00049023 -
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00004911 -
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
|
Phase 1/Phase 2 | |
Completed |
NCT00004910 -
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
|
Phase 1/Phase 2 | |
Completed |
NCT00006368 -
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00730483 -
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00602082 -
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00017199 -
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
|
Phase 2 |